Biosafety and pharmacokinetic characteristics of polyethylene pyrrolidone modified nano selenium in rats.

Autor: Li W; School of Nuclear Science and Technology, University of South China, 28 West Changsheng Road, Hengyang, Hunan, 421001, China.; The Affiliated Nanhua Hospital, University of South China, 336 Dongfeng South Road, Zhuhui District, Hengyang, Hunan, 421002, China., Lu X; The Affiliated Nanhua Hospital, University of South China, 336 Dongfeng South Road, Zhuhui District, Hengyang, Hunan, 421002, China., Jiang L; The Affiliated Nanhua Hospital, University of South China, 336 Dongfeng South Road, Zhuhui District, Hengyang, Hunan, 421002, China., Wang X; School of Nuclear Science and Technology, University of South China, 28 West Changsheng Road, Hengyang, Hunan, 421001, China. xiangjiang_wang@sina.com.; Hunan Provincial Key Laboratory of Emergency Safety Operation Technology and Equipment for Nuclear Facilities, 28 West Changsheng Road, Hengyang, 421001, Hunan, China. xiangjiang_wang@sina.com.
Jazyk: angličtina
Zdroj: BMC biotechnology [BMC Biotechnol] 2024 Nov 28; Vol. 24 (1), pp. 98. Date of Electronic Publication: 2024 Nov 28.
DOI: 10.1186/s12896-024-00915-9
Abstrakt: Objective: This study aims to investigate the biocompatibility and pharmacokinetic characteristics of polyvinyl pyrrolidone-modified selenium nanoparticles (PVP-Se NPs). Understanding the biosafety of PVP-Se NPs is crucial due to their potential applications in mitigating oxidative stress-related diseases and improving drug delivery systems.
Methods: Selenium nanoparticles were prepared using a sodium selenite solution, followed by PVP modification. Particle size analysis was conducted using dynamic light scattering (DLS), and particle morphology was observed using transmission electron microscopy (TEM). Different concentrations of PVP-Se NPs were intraperitoneally injected into SD rats, and the survival rate was observed. Liver and kidney tissues, urine, feces, and blood samples were collected at the highest safe dose, and the concentration of selenium ions was measured.
Results: The average particle size of PVP-Se NPs was 278.4 ± 124.8 nm, exhibiting a semi-spherical shape. The maximum safe dose of PVP-Se NPs for intraperitoneal injection in rats was approximately 320 µg/kg. At this dose, the content of PVP-Se NPs significantly increased in the liver and kidney tissues from day 1 to day 3, in urine and feces during the first 8 h, and in blood during the first 2 h, followed by a gradual decrease.
Conclusion: When administered at a safe dose, PVP-Se NPs do not damage liver and kidney tissues and can be eliminated from the body through liver and kidney metabolism without accumulation.
Competing Interests: Declarations. Ethical approval: This study is approved by the Ethics Committee of the Affiliated Nanhua Hospital, University of South China (NO. 2022-ky-21). All animal studies and experiments were conducted in accordance with animal care standards and the guidelines of the institutional animal ethics committee. Consent for publication: The work described has not been published previously. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje